BEIJING, Nov. 13, 2020 /PRNewswire/ -- China Biologic
Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the
"Company"), a leading fully integrated plasma-based
biopharmaceutical company in China, today announced that the Company plans
to release its third quarter 2020 financial results on Tuesday, November 24, 2020 after the market
closes.
The Company's management will hold a conference call at
7:30 a.m. ET on Wednesday,
November 25, 2020, which is 8:30 p.m.
Beijing Time on November 25, 2020, to
discuss third quarter 2020 results. Listeners may access the call
by dialing:
|
US:
|
1 888 346
8982
|
|
International:
|
1 412 902
4272
|
|
Hong Kong:
|
800 905945
|
|
Mainland
China:
|
4001
201203
|
A telephone replay will be available one hour after the
conclusion of the conference call through December 2, 2020. The dial-in details are:
|
US:
|
1 877 344
7529
|
|
International:
|
1 412 317
0088
|
|
Passcode:
|
10149967
|
A live and archived webcast of the conference call will be
available through the Company's investor relations website at
http://chinabiologic.investorroom.com/.
About China Biologic Products Holdings, Inc.
China Biologic Products Holdings, Inc. (NASDAQ: CBPO) is a
leading fully integrated plasma-based biopharmaceutical company in
China. The Company's products are
used as critical therapies during medical emergencies and for the
prevention and treatment of life-threatening diseases and
immune-deficiency related diseases. China Biologic is headquartered
in Beijing and manufactures over
20 different dosage forms of plasma products through its indirect
majority-owned subsidiary, Shandong Taibang Biological Products
Co., Ltd. and its wholly owned subsidiary, Guizhou Taibang
Biological Products Co., Ltd. The Company also has an equity
investment in Xi'an Huitian Blood Products Co., Ltd. Since the
acquisition of TianXinFu (Beijing)
Medical Appliance Co., Ltd. in 2018, China Biologic is also engaged
in the sale of medical devices, primarily regenerative medical
biomaterial products. The Company sells its products to hospitals,
distributors and other healthcare facilities in China. For additional information, please see
the Company's website www.chinabiologic.com.
Contact:
China Biologic
Products Holdings, Inc.
Mr. Ming Yin
Senior Vice President
Email: ir@chinabiologic.com
The Foote Group
Mr. Philip Lisio
Phone: +86-135-0116-6560
E-mail: phil@thefootegroup.com
View original
content:http://www.prnewswire.com/news-releases/china-biologic-products-to-report-third-quarter-2020-financial-results-301172617.html
SOURCE China Biologic Products Holdings, Inc.